Research programme: NaV1.8 inhibitor pain therapeutics - Vertex Pharmaceuticals
Latest Information Update: 28 May 2025
At a glance
- Originator Vertex Pharmaceuticals
- Class Analgesics; Small molecules
- Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Musculoskeletal pain; Neuropathic pain; Pain
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Musculoskeletal-pain in USA
- 28 May 2025 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
- 28 Jan 2023 No recent reports of development identified for preclinical development in Pain in USA